MFA
ANIP icon

McClarren Financial Advisors’s ANI Pharmaceuticals ANIP Stock Holding History

McClarren Financial Advisors’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3
Closed – – 285
2021
Q2 		$0 Buy
+3
New +$102 ﹤0.01% 312

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $486M AUM 50.29% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

McClarren Financial Advisors's ANIP Position: Q3 2021 in Review

McClarren Financial Advisors sold out of ANI Pharmaceuticals (ANIP) in Q3 2021, closing a stake of 3 shares.

McClarren Financial Advisors first reported a position in ANIP in Q2 2021 and held it in 1 quarter. The position peaked at $0 in Q2 2021. 117 funds tracked by Wall St. Rank hold ANIP as of Q3 2021.

  • McClarren Financial Advisors reported no remaining ANI Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • McClarren Financial Advisors sold 3 ANI Pharmaceuticals shares in Q3 2021.
  • McClarren Financial Advisors first reported a position in ANI Pharmaceuticals in Q2 2021 and held it in 1 quarter.
  • McClarren Financial Advisors's ANI Pharmaceuticals position peaked at $0 in Q2 2021.
  • 117 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q3 2021.

Based on McClarren Financial Advisors's 13F filing for Q3 2021, filed 15 Oct 2021.